LUBBOCK, Texas, June 5, 2012 /PRNewswire/ -- Positron Corporation a leading molecular imaging healthcare company, specializing in the field of nuclear cardiology announces completion of its first strontium validation effort. In May 2012, Manhattan Isotope Technology (MIT), a Positron subsidiary, successfully processed strontium. The internal analysis of the product demonstrates it meets the Sr-82 purity specifications required for the formulation of Sr-82/Rb-82 generators. MIT has now generated the necessary data required for its Drug Master File (DMF) and will be submitting its DMF to the FDA shortly. The second validation sample from the ARRONAX Cyclotron Facility in Nantes, France is set for strontium processing later this month.
Jason Kitten, President of MIT, commented on completion of this milestone, “This is the first strontium-82 validation to be performed outside of the national laboratory arena and sets the stage for private entry into the strontium-82 radioisotope supply chain. The objective of Positron’s isotopes mission is to improve the reliability and increase the availability of Sr-82 supply; further advancing cardiac PET. Positron’s dedication to cardiac PET will lead the way in liberating the United States dependency on reactor-based isotopes, thereby reducing the need for highly enriched uranium. Sr-82 production, processing, and Rb-82 PET are well-established technologies; the techniques, modalities, and know-how have been available for some time and only now, though Positron’s vertically integrated strategy, a full solution is becoming a reality.”
About Positron: Positron Corporation is a leading molecular imaging healthcare company providing innovative nuclear medicine technologies and solutions that are reshaping the field of nuclear cardiology. Through proprietary PET imaging systems, services and radiopharmaceutical solutions, Positron enables healthcare providers to more accurately diagnose disease and improve patient outcomes while practicing cost effective medicine. Positron has gained significant traction in a diverse industry and continues their strong commitment to excellence and advancing cardiac imaging solutions. More information about Positron is available at www.positron.com.
Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as “Risk Factors” in our filings with the Securities and Exchange Commission.
SOURCE Positron Corporation
